Metavention’s Renal Denervation Pivotal IDE Study now Approved by FDA for the Treatment of Hypertension Jun 21, 2023 Read More
Metavention Completes U.S. Enrollment in Groundbreaking Feasibility Study to Treat Type 2 Diabetes Jan 31, 2022 Read More
Metavention Announces Initiation of Groundbreaking Multi-Organ Denervation Study May 03, 2021 Read More
Metavention Announces Initiation of U.S. Clinical Trial for Novel Treatment of Type 2 Diabetes Feb 17, 2021 Read More
Metavention, Inc., Closes $65 Million in Series C Funding, Appoints New Chief Executive Officer Jan 08, 2018 Read More